Clinical Trial: A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07015983) titled 'A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)' on May 30.

Brief Summary: The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Lupus Erythematosus, Systemic Lupus Nephritis

Intervention: DRUG: CC-97540

Specified dose on specified days

DRUG: Fludarabine

Specified dose...